Sun Pharma FY26 Net Profit Rises 5% to ₹114.8 Billion

Sun Pharma reported 11.9% YoY growth in FY26 consolidated revenue to ₹582.2 billion and 5% rise in net profit to ₹114.8 billion.
The Board recommended a final dividend of ₹5 per share, bringing total FY26 dividend to ₹16 per share, maintaining last year's payout.
Auditors issued an unmodified opinion on both standalone and consolidated financial results for the quarter and year ended March 31, 2026.
The company completed several strategic initiatives including the acquisition of Valstar SA and settlement of legacy legal matters during the year.